RecruitingPhase 1NCT06859762

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL217 in Patients With Advanced Solid Tumors

Sponsor

MediLink Therapeutics (Suzhou) Co., Ltd.

Enrollment

630 participants

Start Date

Jul 2, 2025

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumor

Summary

A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called YL217, a drug called YL217, and others for people with advanced solid tumor. The study is currently recruiting participants at 19 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGYL217

Patients will receive specific dose of YL217 administered via intravenous(IV)infusion.

DRUGBevacizumab

Participants will receive bevacizumab administered via intravenous(IV) infusion,at 5mg/kg,Q2W.

DRUG5-FU with leucovorin

Participants will receive 5 fluorouracil 2400mg/m2 and leucovorin 400mg/m2, administered via intravenous (IV) infusion, Q2W

Locations(21)

Mayo Clinic Arizona

Phoenix, Arizona, United States

UCLA Hematology/Oncology - Santa Monica

Santa Monica, California, United States

Yale Cancer Center

New Haven, Connecticut, United States

The University of Kansas Cancer Center (KUCC)

Kansas City, Kansas, United States

Karmanos Cancer Institute

Detroit, Michigan, United States

Columbia University Irving Medical Center

New York, New York, United States

Duke University Medical Center (DUMC)

Durham, North Carolina, United States

University of Cincinnati Medical Center

Cincinnati, Ohio, United States

Cleveland Clinic Taussig Cancer Institute

Cleveland, Ohio, United States

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States

UT Health San Antonio - Mays Cancer Center

San Antonio, Texas, United States

University of Wisconsin Health - UW Carbone Cancer Center

Madison, Wisconsin, United States

Peking Union Medical College Hospital

Beijing, Bejing, China

The Sixth Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, China

The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China

The First Affiliated Hospital of China Medical University

Shenyang, Liaoning, China

Cancer Hospital of Shandong First Medical University

Jinan, Shandong, China

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, China

Tianjin Medical University Cancer Institute & Hospital

Tianjin, Tianjin Municipality, China

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06859762

Related Trials

Study of D3L-002 in Subjects With Advanced Solid Tumors

NCT07667842

A Study of HG381 Administered to Patients With Advanced Solid Tumors

NCT049984221 location

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT0526762618 locations

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors

NCT0695332310 locations

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT0617247885 locations